Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European stocks log steepest one-day fall this year as banks extend slide

Mon, 13th Mar 2023 17:13

European banks log worst two-day selloff in a year

*

Credit Suisse tumbles to fresh record low

*

HSBC rescues Silicon Valley Bank's UK arm

*

Energy firms dip on lower oil prices

March 13 (Reuters) - European stocks logged their steepest one-day fall this year on Monday on continued drag from banking stocks even as authorities stepped in to limit the fallout from the sudden collapse of Silicon Valley Bank.

The pan-European STOXX 600 index closed the day 2.3% lower, with bank, financials and insurer stocks, along with energy stocks, bearing the brunt of selling pressure.

European banking stocks dropped 5.7%, notching their worst two-day selloff since the Russia-Ukraine war broke out early last year.

Worries around the resilience of the sector's balance sheet in the face of SVB's collapse have rattled investors.

"Investors have been shaken by the events of the past few days, and are waiting with bated breath to see if repercussions in the financial sector will spill over and create pools of fresh problems," said Susannah Streeter, head of money and markets at Hargreaves Lansdown.

The wider risk-off moves sent Credit Suisse shares down 9.6% to a fresh record low.

Germany's Commerzbank slumped 12.7%, France's Societe Generale and Spain's Sabadell fell 6.2% and 11.4%, respectively.

HSBC dropped 4.1% after the British bank acquired the UK subsidiary of SVB for 1 pound, rescuing a key lender for technology start-ups in Britain.

However, euro zone banking supervisors saw limited consequences for the region's banks from the collapse of the U.S. lenders, while Moody's Investors Service noted that Europe's banks were unlikely to get hit by bond portfolio losses.

In addition, Morgan Stanley analysts noted that strong liquidity in European banks' balance sheet structure should avoid any forced unwinding or selling of bond portfolios.

The Federal Reserve and U.S. Treasury have announced a range of measures to stabilise the banking system and said SVB depositors would have access to their deposits on Monday.

Meanwhile, the stress in the financial sector has sparked expectations of a slowdown in the Fed's aggressive monetary tightening, with investors seeing a 68% chance of a 25 basis points (bps) hike next week, a drastic change from the 50-bps hike priced in previously.

Goldman Sachs no longer expects a rate hike from the Fed.

On the other hand, the ECB looks set to hike rates by 50 bps later this week.

Among others, Shell, BP and TotalEnergies SE lost between 4% and 5% tracking lower oil prices.

France's Sanofi SA dropped 1.7% on plans to acquire Provention Bio Inc for $2.9 billion. (Reporting by Sruthi Shankar and Ankika Biswas in Bengaluru; Editing by Savio D'Souza, Uttaresh Venkateshwaran and Christina Fincher)

More News
12 Aug 2022 11:00

Drugmakers' shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi , Haleon and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
12 Aug 2022 09:01

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
11 Aug 2022 22:15

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 18:45

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 17:29

European shares tick higher; Aegon shines on forecast raise

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

Read more
11 Aug 2022 12:23

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

Read more
10 Aug 2022 17:02

European bourses hold on to U.S. CPI boost

Aug 10 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

EUROPEAN BOURSES HOLD ON TO U.S. CPI BOOST (1150 EDT/1550 GMT)

Read more
9 Aug 2022 16:59

European shares slip with U.S. inflation data in focus

Aug 9 (Reuters) - European shares dipped on Tuesday as investors cautiously waited for key U.S. inflation data later in the week for hints on the Federal Reserve's next move on interest rate increases.

Read more
28 Jul 2022 07:20

Sanofi lifts profit outlook as Dupixent sales surge 43%

July 28 (Reuters) - French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.

Read more
19 Jul 2022 13:00

As COVID patent war rages on, pharma group seeks fairer future access

LONDON, July 19 (Reuters) - An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for COVID-19 interventions between the pharmaceutical industry and developing nations endures.

Read more
18 Jul 2022 12:19

GSK's consumer arm Haleon debuts with lacklustre valuation

LONDON, July 18 (Reuters) - British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of the price rival Unilever offered to pay earlier this year.

Read more
7 Jul 2022 15:25

EU drugs regulator open to COVID boosters that target older Omicron offshoots

LONDON, July 7 (Reuters) - The European Medicines Agency (EMA) is open to using next generation COVID-19 vaccines that target older offshoots of the Omicron variant this fall, an official said on Thursday, amid a rise in cases due to new Omicron subvariants.

Read more
24 Jun 2022 17:19

European shares mark strong end to nervous week

June 24 (Reuters) - European stocks jumped 2.6% on Friday, pushing them into positive territory for the week as investors started to scale back central bank tightening bets, spurring inflows into risky assets.

Read more
24 Jun 2022 17:08

Defensive stocks lead rebound in FTSE 100

June 24 (Reuters) - UK's FTSE 100 rose on Friday, lifted by defensive stocks at the end of a choppy week that saw investor anxiety over hawkish central banks, weak economic readings and heightened risks of a global recession.

Read more
24 Jun 2022 09:51

Sanofi, GSK variant-specific COVID shot found effective against Omicron

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.